Melisa Cooper
YOU?
Author Swipe
View article: Vascular Endothelial Growth Factor–B Blockade with CSL346 in Diabetic Kidney Disease
Vascular Endothelial Growth Factor–B Blockade with CSL346 in Diabetic Kidney Disease Open
Key Points The vascular endothelial growth factor B inhibitor CSL346 (8 or 16 mg/kg q4w) did not reduce urinary albumin-creatinine ratio at week 16 versus placebo in patients with type 2 diabetes mellitus and diabetic kidney disease. CSL34…